(Q41661156)

English

Correlation of serum cytokine and acute phase reactant levels with alterations in weight and serum albumin in patients receiving immunotherapy with recombinant IL-2.

scientific article published on March 1994

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

6 October 2017

Correlation of serum cytokine and acute phase reactant levels with alterations in weight and serum albumin in patients receiving immunotherapy with recombinant IL-2. (English)

1 reference

Europe PubMed Central

6 October 2017

1 reference

based on heuristic

inferred from title

author name string

Deehan DJ

1

1 reference

Europe PubMed Central

6 October 2017

Heys SD

2

1 reference

Europe PubMed Central

6 October 2017

Simpson W

3

1 reference

Europe PubMed Central

6 October 2017

Herriot R

4

1 reference

Europe PubMed Central

6 October 2017

Broom J

5

1 reference

Europe PubMed Central

6 October 2017

Eremin O

6

1 reference

Europe PubMed Central

6 October 2017

publication date

1 March 1994

1 reference

Europe PubMed Central

6 October 2017

Clinical and Experimental Immunology

1 reference

Europe PubMed Central

6 October 2017

95

1 reference

Europe PubMed Central

6 October 2017

3

1 reference

Europe PubMed Central

6 October 2017

366-372

1 reference

Europe PubMed Central

6 October 2017

The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.1994.TB07005.X

21 January 2018

Plasma tumor necrosis factor in patients with septic shock. Mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.1994.TB07005.X

21 January 2018

High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.1994.TB07005.X

21 January 2018

Temporal sequence and cellular origin of interleukin-2 stimulated cytokine gene expression

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.1994.TB07005.X

21 January 2018

The protein metabolic response to short-term starvation in man.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1535097

13 September 2018

Complement activation by C-reactive protein complexes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1535097

13 September 2018

Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1535097

13 September 2018

Clinical effects and toxicity of interleukin-2 in patients with cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1535097

13 September 2018

Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1535097

13 September 2018

Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1535097

13 September 2018

Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1535097

13 September 2018

IL-2 induces pulmonary edema and vasoconstriction independent of circulating lymphocytes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1535097

13 September 2018

Cardiorespiratory effects of immunotherapy with interleukin-2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1535097

13 September 2018

The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1535097

13 September 2018

Administration of recombinant IL-2 augments the level of serum IgM in an IL-2 deficient patient

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1535097

13 September 2018

Induction of endogenous cytokine-mRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1535097

13 September 2018

Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1535097

13 September 2018

Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1535097

13 September 2018

Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1535097

13 September 2018

Activation of the complement system during immunotherapy with recombinant IL-2. Relation to the development of side effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1535097

13 September 2018

Tumor necrosis factor alpha/cachectin stimulates eosinophil oxidant production and toxicity towards human endothelium

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1535097

13 September 2018

Immunopathological changes in the skin following recombinant interleukin-2 treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1535097

13 September 2018

Molecular features of CD34: a hemopoietic progenitor cell-associated molecule

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1535097

13 September 2018

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1535097

13 September 2018

Role of IL-5 in IL-2-induced eosinophilia. In vivo and in vitro expression of IL-5 mRNA by IL-2

1 reference

https://pubmed.ncbi.nlm.nih.gov/7511074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/7511074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/7511074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum levels of interleukin-6 and acute phase responses

1 reference

https://pubmed.ncbi.nlm.nih.gov/7511074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Myocarditis or acute myocardial infarction associated with interleukin-2 therapy for cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/7511074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): binding of complement and C-reactive protein by IL-2-activated lymphocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/7511074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/7511074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lymphocytes stimulated by allogeneic B cell lines cleave the third component of complement and fix C3 fragments. Their nonspecific lytic capacity is elevated against complement receptor type 2-carrying targets

1 reference

https://pubmed.ncbi.nlm.nih.gov/7511074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activation of the complement system in the adult respiratory distress syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/7511074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reciprocal expression of CD34 and cell adhesion molecule ELAM-1 on vascular endothelium in acute cutaneous graft-versus-host disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/7511074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/7511074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of natural and recombinant IL 2 on regulation of IFN gamma production and natural killer activity: lack of involvement of the Tac antigen for these immunoregulatory effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/7511074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dermatologic changes associated with interleukin 2 administration

1 reference

https://pubmed.ncbi.nlm.nih.gov/7511074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://pubmed.ncbi.nlm.nih.gov/7511074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic Values of Tumor Necrosis Factor/Cachectin, Interleukin-l, Interferon- , and Interferon- in the Serum of Patients with Septic Shock

1 reference

https://pubmed.ncbi.nlm.nih.gov/7511074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-2 treatment-associated eosinophilia is mediated by interleukin-5 production

1 reference

https://pubmed.ncbi.nlm.nih.gov/7511074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1365-2249.1994.TB07005.X

1 reference

Europe PubMed Central

6 October 2017

0 references

1 reference

Europe PubMed Central

6 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41661156&oldid=1537640566"